Works matching IS 0741238X AND DT 2025 AND VI 42 AND IP 5

Results: 34
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2480, doi. 10.1007/s12325-025-03142-6
    By:
    • Wu, Xiaohua;
    • Mao, Yimin;
    • Xu, Nong;
    • Bai, Yuxian;
    • Wang, Dong;
    • Chen, Xiaojun;
    • Yin, Xianli;
    • Deng, Yanhong;
    • Yang, Jianwei;
    • Zhang, Jieqing;
    • Tang, Jie;
    • Huang, Yi;
    • Li, Jiayi;
    • Luo, Suxia;
    • Zheng, Hong;
    • Zhao, Weidong;
    • Xu, Miaomiao;
    • Li, Nan;
    • Mao, Yixiang;
    • Gozman, Alexander
    Publication type:
    Article
    21
    22
    23
    24
    25

    First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2248, doi. 10.1007/s12325-025-03133-7
    By:
    • Moehler, Markus;
    • Oh, Do-Youn;
    • Kato, Ken;
    • Arkenau, Tobias;
    • Tabernero, Josep;
    • Lee, Keun-Wook;
    • Rha, Sun Young;
    • Hirano, Hidekazu;
    • Spigel, David;
    • Yamaguchi, Kensei;
    • Wyrwicz, Lucjan;
    • Disel, Umut;
    • Pazo-Cid, Roberto A.;
    • Fornaro, Lorenzo;
    • Xu, Yaling;
    • Sheng, Tao;
    • Yang, Silu;
    • Kadva, Alysha;
    • Cruz-Correa, Marcia;
    • Xu, Rui-Hua
    Publication type:
    Article
    26
    27
    28
    29
    30

    First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2269, doi. 10.1007/s12325-025-03115-9
    By:
    • Xu, Jianming;
    • Kato, Ken;
    • Hubner, Richard;
    • Park, Sook Ryun;
    • Kojima, Takashi;
    • Ishihara, Ryu;
    • Wyrwicz, Lucjan;
    • Van Cutsem, Eric;
    • Jimenez-Fonseca, Paula;
    • Wu, Hongqian;
    • Wang, Lei;
    • Yan, Sebastian;
    • Shi, Jingwen;
    • Kadva, Alysha;
    • Yoon, Harry H.
    Publication type:
    Article
    31
    32
    33

    Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2015, doi. 10.1007/s12325-024-03080-9
    By:
    • Oaknin, Ana;
    • Lee, Jung-Yun;
    • Makker, Vicky;
    • Oh, Do-Youn;
    • Banerjee, Susana;
    • González-Martín, Antonio;
    • Jung, Kyung Hae;
    • Ługowska, Iwona;
    • Manso, Luis;
    • Manzano, Aránzazu;
    • Melichar, Bohuslav;
    • Siena, Salvatore;
    • Stroyakovskiy, Daniil;
    • Fielding, Anitra;
    • Puvvada, Soham;
    • Smith, Ann;
    • Meric-Bernstam, Funda
    Publication type:
    Article
    34

    Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2040, doi. 10.1007/s12325-025-03117-7
    By:
    • Wang, Xuan;
    • Pahwa, Ankit;
    • Bausch-Jurken, Mary T.;
    • Chitkara, Anushri;
    • Sharma, Pawana;
    • Malmenäs, Mia;
    • Vats, Sonam;
    • Whitfield, Michael Gordon;
    • Lai, Kira Zhi Hua;
    • Dasari, Priyadarsini;
    • Gupta, Ritu;
    • Nassim, Maria;
    • Van de Velde, Nicolas;
    • Green, Nathan;
    • Beck, Ekkehard
    Publication type:
    Article